Cancer is one of the biggest burdens for modern societies. Its diagnosis causes grief to patients and relatives and despite the research on the area incidences keep increasing. Pancreatic cancer is the 14th most common cancer type worldwide it tops for the 4th one in cancer related deaths in Europe. A large proportion of the patients die within a year after the clinical diagnosis. Cancer cells suffer from faulty cell respiration and exhibit an increased usage of glucose, the so-called Warburg effect, that allows them to boost their growth rate, survival and proliferation. This metabolic pathway consisting of an aerobic glycolysis to produce pyruvate, followed by lactate fermentation could be a therapeutic target. Reducing the glucose intake and feeding cancer with ketone bodies, a bypass to the cancer metabolism, could reduce cancer growth by limiting their energy source. On the other hand, vitamin D has shown beneficial effects when treating cancer. Outcomes from trials have shown that cancer could be inhibited or delayed by dietary supplements of vitamin D. Here we hypothesise that the treatment of pancreas cancer cells with ketone bodies together with vitamin D reduces cell proliferation. In vitro culture of Panc1 cells treated in combination with 1,25-vitamin D has shown significant effects, both for sodium-3-hydroxybutyrate and lithium-acetoacetate (p<0,01). Findings show that a ketogenic approach to fight cancer is very promising, but foremost totally normal for the organism.